Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Trial of Single-agent Cetuximab Dose Escalated to Rash in Patients With Persistent or Recurrent Epithelial Ovarian or Primary Peritoneal Carcinoma

NCT00082212 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.

NCT NCT00082212
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00082212 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Trial of Single-agent Cetuximab Dose Escalated to Rash in Patients With Persistent or Recurrent Epithelial Ovarian or Primary Peritoneal Carcinoma
Lead sponsor
Eli Lilly and Company
Phase
Phase 2
Overall status
Terminated
Start date
November 30, 2004
Completion date
June 30, 2007
Enrollment
25 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

ovarian cancer